Colgate-Palmolive Company (NYSE: CL): Corporate Profile & Financials

By Raveendran R | Updated on: November 15, 2026

Source: Colgate-Palmolive Company Form 10-K 2025

Colgate-Palmolive Company is an international consumer products enterprise organized around the corporate purpose of reimagining a healthier future for all people, their pets, and the planet. The company centers its global business architecture on two overarching product segments: Oral, Personal and Home Care; and Pet Nutrition.

Core Business Segments & Operating Lines:
  • Latin America Profit Driver: Latin America represented the largest individual operating profit contributor among operating regions at $1,411 million, generating a segment operating margin of 29.6% on net sales of…
  • Hill’s Pet Nutrition Expansion: Pet Nutrition advanced net sales by 2.9% to $4,613 million and operating profit by 10% to $1,064 million, achieving an operating profit margin of 23.1%.
Metrics for FY 2025
Income Statement Metrics
Revenue
$20.38 B (▲ 1.4%)
Prev Year: $20.10 B
Gross Profit
$12.25 B (▲ 0.7%)
Prev Year: $12.16 B
Operating Profit
$3.31 B (▼ 22.5%)
Prev Year: $4.27 B
Net Profit
$2.13 B (▼ 26.2%)
Prev Year: $2.89 B
Gross Margin
60.11 % (▼ 39 bps)
Prev Year: 60.50 %
Operating Margin
16.22 % (▼ 501 bps)
Prev Year: 21.23 %
PAT Margin
10.46 % (▼ 391 bps)
Prev Year: 14.37 %
Asset Turnover
1.25x (▼ 0.00 pts)
Prev Year: 1.25x
Return & Capital Efficiency Metrics
ROE
584.11 % (▲ 5304 bps)
Prev Year: 531.07 %
ROCE
34.88 % (▼ 660 bps)
Prev Year: 41.49 %
ROC
39.58 % (▼ 1067 bps)
Prev Year: 50.25 %
ROA
13.06 % (▼ 495 bps)
Prev Year: 18.00 %
Cash ROE
1150.14 % (▲ 39517 bps)
Prev Year: 754.96 %
Cash ROCE
44.30 % (▲ 437 bps)
Prev Year: 39.92 %
Cash ROC
50.26 % (▲ 190 bps)
Prev Year: 48.36 %
Cash ROA
25.71 % (▲ 11 bps)
Prev Year: 25.60 %
3Y Avg ROE
512.66 %
3Y Avg ROCE
38.37 %
3Y Avg ROC
45.58 %
3Y Avg ROA
15.13 %
Balance Sheet Metrics
Total Assets
$16.33 B (▲ 1.8%)
Prev Year: $16.05 B
Current Assets
$5.71 B (▲ 7.4%)
Prev Year: $5.32 B
Total Liabilities
$15.96 B (▲ 3.0%)
Prev Year: $15.50 B
Current Liabilities
$6.85 B (▲ 19.0%)
Prev Year: $5.76 B
Capital Employed
$9.48 B (▼ 7.9%)
Prev Year: $10.29 B
Total Debt
$7.99 B (▲ 0.5%)
Prev Year: $7.95 B
Total Equity
$365.00 M (▼ 32.9%)
Prev Year: $544.00 M
Working Capital
-$1.14 B (▼ 158.8%)
Prev Year: -$442.00 M
Current Ratio
0.83x (▼ 0.09 pts)
Prev Year: 0.92x
Debt to Equity
21.88x (▲ 7.27 pts)
Prev Year: 14.61x
Debt to Assets
0.49x (▼ 0.01 pts)
Prev Year: 0.50x
Equity Multiplier
44.74x (▲ 15.24 pts)
Prev Year: 29.50x
Cash Flow Metrics
Operating Cash Flow
$4.20 B (▲ 2.2%)
Prev Year: $4.11 B
CapEx
$564.00 M (▲ 0.5%)
Prev Year: $561.00 M
Free Cash Flow
$3.63 B (▲ 2.5%)
Prev Year: $3.55 B
OCF Margin
20.60 % (▲ 16 bps)
Prev Year: 20.43 %
FCF Margin
17.83 % (▲ 19 bps)
Prev Year: 17.64 %
CF to Debt
0.53x (▲ 0.01 pts)
Prev Year: 0.52x

📋 Quick Facts / Company Snapshot: Colgate-Palmolive Company

Metric / Attribute Disclosed Detail
Official Company Name Colgate-Palmolive Company
Ticker Symbol CL
Primary Exchange New York Stock Exchange
Commission File Number 1-644
I.R.S. Employer Identification No. 13-1815595
State of Incorporation Delaware
Year of Incorporation 1923 (Founded in 1806)
Principal Executive Offices 300 Park Avenue, New York, New York 10022
Telephone Number 212-310-2000
Chairman of the Board, President & CEO Noel Wallace
Chief Financial Officer Stanley J. Sutula III
Total Global Workforce Approximately 33,600 employees
Geographic Employee Distribution Over 84% outside the United States across more than 100 countries
Operating Business Segments Oral, Personal and Home Care; Pet Nutrition
Geographic Management Structure North America, Latin America, Europe, Asia Pacific, Africa/Eurasia, Hill’s Pet Nutrition
Commercial Footprint Products marketed in over 200 countries and territories (Pet Nutrition in over 80)
Total Operating Properties Approximately 325 properties owned or leased worldwide
Major Customer Concentration Walmart, Inc. and its affiliates (approximately 11% of consolidated Net sales)
Recent Major Acquisition Care TopCo Pty Ltd (owner of Prime100 pet food business)
External Corporate Website www.colgatepalmolive.com

1. Corporate Identity: Colgate-Palmolive Company Overview & History

The Big Picture

Colgate-Palmolive Company is an international consumer products enterprise organized around the corporate purpose of reimagining a healthier future for all people, their pets, and the planet. The company centers its global business architecture on two overarching product segments: Oral, Personal and Home Care; and Pet Nutrition. Across these units, the enterprise manufactures, sources, distributes, and markets consumer goods in more than 200 countries and territories worldwide, maintaining operations in specialized health categories, everyday hygiene lines, and science-led therapeutic animal wellness.

The enterprise focuses its overarching commercial agenda on driving organic sales expansion, compounding dollar-based diluted earnings per share, optimizing manufacturing and logistics productivity, and generating strong free cash flow supported by balanced capital deployment. Geographic diversification serves as a cornerstone of the business model, with approximately two-thirds of net sales originating outside the United States and roughly 45% derived from emerging geographic markets, including Latin America, Asia (excluding Japan), Africa/Eurasia, and Central Europe.

  • Core Strategic Framework: Scaling organic sales through core and premium science-based product innovation, disciplined omni-channel demand generation, enterprise data and artificial intelligence (“AI”) capabilities, and end-to-end supply chain agility.
  • Segment Revenue Distribution: In 2025, Oral Care represented 44%, Pet Nutrition represented 23%, Personal Care accounted for 17%, and Home Care constituted 16% of total worldwide Net sales.

The Founders & Their Legacy

The business traces its continuous commercial lineage back to 1806, when it was initially established as an American enterprise. Over more than two centuries of corporate evolution, the entity expanded from its early manufacturing roots into a global consumer brand powerhouse. The modern corporation was formally incorporated under the laws of the State of Delaware in 1923.

The long-term heritage of the enterprise is anchored in the development of globally penetrated trademarks in household oral hygiene and skin cleansing. The foundational equities established under the Colgate, Palmolive, and associated family banners have been expanded systematically through internal laboratory research, brand acquisitions, and international market penetration.

The Journey: History & Evolution

Throughout its operating history, Colgate-Palmolive transitioned from a traditional domestic soap and candle producer into an omni-channel global business. A defining strategic transition occurred in 1995 with the acquisition of the Kolynos oral care business in Latin America from Wyeth, solidifying the enterprise’s oral health leadership across South America.

In subsequent decades, the company broadened its focus beyond baseline mass hygiene into therapeutic oral therapies, active personal cleansing, high-efficacy surface cleaning, and premium therapeutic pet diet formulations through Hill’s Pet Nutrition. The company has navigated changing global trade landscapes, periodic restructuring programs, and portfolio additions to reinforce its international market footprint across high-margin segments.

The Corporate Umbrella

The parent entity, Colgate-Palmolive Company, acts as the primary publicly traded corporation holding equity ownership in domestic and international operating subsidiaries across North America, Latin America, Europe, Asia Pacific, Africa, and Eurasia. The enterprise executes centralized treasury, executive governance, legal compliance, and strategic planning functions from its global headquarters in New York City.

During the fiscal year ended December 31, 2025, the parent enterprise expanded its operating perimeter through strategic additions. On April 30, 2025, the company completed the acquisition of Care TopCo Pty Ltd, the corporate parent and owner of the Prime100 pet food business in Australia, integrating fresh pet nutrition capabilities directly into the worldwide Hill’s Pet Nutrition operational structure.

2. The Business Engine: Colgate-Palmolive Company Business Model & Revenue Segments

The Core Divisions

The enterprise conducts business operations through two primary product segments: Oral, Personal and Home Care; and Pet Nutrition. For internal operational oversight and external financial evaluation, the Oral, Personal and Home Care business is managed across five regional operating segments: North America, Latin America, Europe, Asia Pacific, and Africa/Eurasia. Hill’s Pet Nutrition operates as a worldwide specialized division, while centralized expenses are aggregated within Corporate.

Reportable Operating Segment 2025 Net Sales (in $ millions) 2025 Operating Profit (Loss) (in $ millions) 2024 Net Sales (in $ millions) 2024 Operating Profit (Loss) (in $ millions) Latest YoY (%)
North America
4,045 784 4,113 839 -1.65%
Latin America
4,776 1,411 4,782 1,526 -0.13%
Europe
2,962 748 2,770 658 +6.93%
Asia Pacific
2,814 760 2,858 812 -1.54%
Africa/Eurasia
1,172 255 1,095 253 +7.03%
Hill’s Pet Nutrition
4,613 1,064 4,483 965 +2.90%
Corporate 0 (1,717) 0 (784) N/M
Total Consolidated Group 20,382 3,306 20,101 4,268 +1.40%

Operating performance across the reportable units reflected divergent macroeconomic and regional dynamics in 2025:

  • Latin America Profit Driver: Latin America represented the largest individual operating profit contributor among operating regions at $1,411 million, generating a segment operating margin of 29.6% on net sales of $4,776 million.
  • Hill’s Pet Nutrition Expansion: Pet Nutrition advanced net sales by 2.9% to $4,613 million and operating profit by 10% to $1,064 million, achieving an operating profit margin of 23.1%.
  • Corporate Segment Charges: Corporate operating loss widened to $(1,717) million in 2025, driven by $919 million of pretax goodwill and intangible assets impairment charges in the skin health reporting unit, $99 million related to an ERISA litigation matter, and $13 million under the Strategic Growth and Productivity Program.

The Global Product Catalog

The company maintains a focused product portfolio organized around daily preventive health, specialized dermatological treatments, household cleaning solutions, and veterinarian-recommended pet diets:

  • Oral Care: Complete regimens including therapeutic toothpastes, manual toothbrushes, whitening products, specialized mouthwashes, and professional dental pharmaceutical lines distributed directly to dentists and oral health professionals.
  • Personal Care: Liquid hand soaps, solid bar soaps, shower cleansing gels, body washes, roll-on and stick deodorants and antiperspirants, daily shampoos, conditioners, and professional-grade skin health treatments.
  • Home Care: Liquid dishwashing detergents, concentrated and multi-surface household cleaners, and concentrated fabric conditioning liquids.
  • Pet Nutrition: Specialized dietary formulations for domestic canines and felines, spanning daily maintenance nutrition, clinical therapeutic formulas prescribed for specific medical conditions, and premium fresh refrigerated pet food.

The Names You Know

The company relies on a globally recognized trademark portfolio that underpins retail customer distribution and consumer purchase frequency across modern, traditional, and digital commerce channels:

  • Oral Care Brands: Colgate, Darlie, elmex, hello, meridol, Sorriso, and Tom’s of Maine.
  • Personal Care & Skin Health Brands: Palmolive, Protex, Softsoap, Irish Spring, Sanex, Lady Speed Stick, Speed Stick, EltaMD, Filorga, and PCA SKIN.
  • Home Care Brands: Ajax, Axion, Fabuloso, Murphy, Suavitel, Soupline, Fluffy, and Cuddly.
  • Pet Nutrition Brands: Hill’s Science Diet (marketed as Hill’s Science Plan in Europe), Hill’s Prescription Diet, and Prime100.

In global market standing, Colgate-Palmolive maintained the leading worldwide market share position in toothpaste at 41.3% for full-year 2025, and maintained global leadership in manual toothbrushes with a 32.4% market share. The business also maintained global leadership in liquid hand soap market share under the Palmolive, Protex, and Softsoap trademarks.

Mapping the Global Reach

The company’s commercial architecture reaches across more than 200 countries, managed through geographic operating structures and regional distribution hubs.

Geographic Segment / Territory 2025 Net Sales (in $ millions) 2024 Net Sales (in $ millions) 2023 Net Sales (in $ millions) Latest YoY (%)
North America
4,045 4,113 4,091 -1.65%
Latin America
4,776 4,782 4,640 -0.13%
Europe
2,962 2,770 2,571 +6.93%
Asia Pacific
2,814 2,858 2,782 -1.54%
Africa/Eurasia
1,172 1,095 1,083 +7.03%
Hill’s Pet Nutrition (Worldwide)
4,613 4,483 4,290 +2.90%
Total Worldwide Net Sales 20,382 20,101 19,457 +1.40%

Within individual country jurisdictions, Net sales in the United States across Oral, Personal and Home Care were $3,596 million in 2025, $3,640 million in 2024, and $3,625 million in 2023. Hill’s Pet Nutrition Net sales in the United States were $3,062 million in 2025, $3,059 million in 2024, and $2,918 million in 2023. Combined United States operations represented approximately one-third of consolidated Net sales.

The Brick & Mortar Footprint

The enterprise conducts global manufacturing, logistical distribution, advanced scientific research, and regional administrative activities across approximately 325 properties worldwide, comprising both owned real estate and operational leasehold commitments.

  • Corporate Headquarters: Located in leased office space at 300 Park Avenue, New York, New York.
  • United States Real Estate: Operations span approximately 85 properties, of which 17 are owned. Major U.S. manufacturing and warehousing facilities for Oral, Personal and Home Care are situated in Ohio, South Carolina, and Tennessee. Pet Nutrition manufacturing and warehousing facilities are located in Indiana, Kansas, Kentucky, Ohio, and Oklahoma.
  • International Facilities: Approximately 240 properties operate outside the U.S. across more than 80 countries, with 59 facilities owned. Major international factories and warehouses for Oral, Personal and Home Care operate in Australia, Brazil, China, Colombia, France, Greece, Guatemala, India, Italy, Mexico, Poland, South Africa, Thailand, Türkiye, and Vietnam. Pet Nutrition maintains international facilities in Australia, Czech Republic, Italy, and the Netherlands.
  • Primary Research & Development Hubs: Centralized R&D for Oral Care and Personal Care is located in New Jersey; Home Care primary research is situated in Mexico; and Pet Nutrition R&D is based in Kansas. The global data center operates in New Jersey.
  • Global Business Shared Services: Shared corporate service hubs operate from leased premises in India, Mexico, and Poland.

3. The Financial Health: Colgate-Palmolive Company (FY 2025) Audited Financial Statements

Earnings, Expenses & Profits: Colgate-Palmolive Company Income Statement

Consolidated Net sales reached $20,382 million in 2025, compared to $20,101 million in 2024 and $19,457 million in 2023. The 1.4% increase in 2025 was driven by a 2.1% net selling price realization and a 0.3% volume contribution from the Prime100 acquisition, partially offset by organic volume declines of 0.4% and an adverse foreign exchange impact of 0.3%.

Consolidated Statements of Income Line Item (in $ millions) 2025 2024 2023 Latest YoY (%)
Net sales 20,382 20,101 19,457 +1.40%
Cost of sales 8,131 7,940 8,131 +2.41%
Gross profit 12,251 12,161 11,326 +0.74%
Selling, general and administrative expenses 7,903 7,729 7,151 +2.25%
Other (income) expense, net 123 164 191 -25.00%
Goodwill and intangible assets impairment charges 919 0 0 N/M
Operating profit 3,306 4,268 3,984 -22.54%
Non-service related postretirement costs 55 87 360 -36.78%
Interest expense 267 292 287 -8.56%
Interest income 75 67 55 +11.94%
Income before income taxes 3,059 3,956 3,392 -22.67%
Provision for income taxes 798 907 937 -12.02%
Net income including noncontrolling interests 2,261 3,049 2,455 -25.84%
Less: Net income attributable to noncontrolling interests 129 160 155 -19.38%
Net income attributable to Colgate-Palmolive Company 2,132 2,889 2,300 -26.20%

Cost of sales increased by 2.4% in 2025 to $8,131 million, causing reported gross profit margin to contract by 40 basis points to 60.1%. Operating profit declined by 22.5% to $3,306 million, primarily reflecting the recognition of $919 million in non-cash pretax impairment charges recorded in the fourth quarter of 2025 to write down goodwill and finite-life intangibles associated with the Filorga skin health business.

  • Impairment Charge Magnitude: The $919 million pretax impairment ($794 million aftertax) reduced skin health goodwill by $582 million and Filorga trademark and customer relationships by $244 million and $93 million, respectively.
  • Diluted EPS Comparison: Diluted earnings per common share finished at $2.63 in 2025, compared to $3.51 in 2024 and $2.77 in 2023. On a non-GAAP basis excluding the impairments, ERISA litigation, restructuring, and acquisition costs, diluted EPS rose 3% to $3.69 from $3.60.
  • Effective Income Tax Rate: The effective income tax rate was 26.1% in 2025, up from 22.9% in 2024, influenced by non-deductible goodwill impairment charges.

Assets, Debts & Equity: Colgate-Palmolive Company Balance Sheet

Colgate-Palmolive ended 2025 with total assets of $16,330 million, compared to $16,046 million at the close of 2024. Current assets totaled $5,709 million, supported by $1,288 million in cash and cash equivalents, $1,675 million in net trade receivables, and $2,032 million in current inventory inventories.

Consolidated Balance Sheets Line Item (in $ millions) 2025 2024 Latest YoY (%)
Cash and cash equivalents 1,288 1,096 +17.52%
Receivables (net of allowances of $90 and $85, respectively) 1,675 1,521 +10.12%
Inventories 2,032 1,987 +2.26%
Other current assets 714 713 +0.14%
Total current assets 5,709 5,317 +7.37%
Property, plant and equipment, net 4,660 4,422 +5.38%
Goodwill 3,122 3,272 -4.58%
Other intangible assets, net 1,536 1,756 -12.53%
Deferred income taxes (non-current asset) 205 195 +5.13%
Other assets 1,098 1,084 +1.29%
Total assets 16,330 16,046 +1.77%
Debt payable within one-year 1,117 660 +69.24%
Accounts payable 2,089 1,805 +15.73%
Accrued income taxes 383 403 -4.96%
Other accruals 3,264 2,891 +12.90%
Total current liabilities 6,853 5,759 +19.00%
Long-term debt 6,871 7,289 -5.73%
Deferred income taxes (non-current liability) 181 343 -47.23%
Other liabilities 2,060 2,111 -2.42%
Total liabilities 15,965 15,502 +2.99%
Common stock, $1 par value 1,466 1,466 0.00%
Additional paid-in capital 4,322 4,181 +3.37%
Retained earnings 26,595 26,145 +1.72%
Accumulated other comprehensive income (loss) (3,879) (4,222) -8.12%
Treasury stock, at cost (28,450) (27,358) +3.99%
Total Colgate-Palmolive Company shareholders’ equity 54 212 -74.53%
Noncontrolling interests 311 332 -6.33%
Total equity 365 544 -32.90%
Total liabilities and equity 16,330 16,046 +1.77%

The company maintains a capital structure characterized by substantial treasury stock repurchases executed over decades, resulting in cumulative Treasury stock at cost of $(28,450) million at December 31, 2025, against Retained earnings of $26,595 million.

  • Debt Profile: Total debt (including current debt of $1,117 million and long-term debt of $6,871 million) was $7,988 million at year-end 2025, compared to $7,949 million in 2024. Commercial paper outstanding dropped to $147 million from $936 million.
  • Liquidity Buffer: The company maintained access to $3,641 million of unused domestic and foreign lines of credit, supported by an undrawn $3,000 million multi-currency revolving credit facility running through November 2030.
  • Working Capital Metrics: Working capital as a percentage of Net sales stood at (7.0)% in 2025 compared to (5.2)% in 2024, demonstrating negative working capital operations where trade accounts payable exceed trade current operating assets.

Cash Flow & Capital Allocation: Colgate-Palmolive Company Cash Flow Statement

Cash provided by operating activities reached $4,198 million in 2025, an increase of 2.2% from $4,107 million generated during 2024. The operational cash flow generation funded capital additions, debt service, common dividends, and the Prime100 acquisition.

Consolidated Statements of Cash Flows Line Item (in $ millions) 2025 2024 2023 Latest YoY (%)
Net income including noncontrolling interests 2,261 3,049 2,455 -25.84%
Depreciation and amortization 630 605 567 +4.13%
ERISA litigation matter 65 0 267 N/M
Restructuring and termination benefits, net of cash (7) 51 (23) N/M
Stock-based compensation expense 155 135 122 +14.81%
Goodwill and intangible assets impairment charges 919 0 0 N/M
Deferred income taxes (109) (77) (98) +41.56%
Cash effects of changes in: Receivables (16) (56) (37) -71.43%
Cash effects of changes in: Inventories 109 (100) 194 N/M
Cash effects of changes in: Accounts payable and other working capital 251 516 309 -51.36%
Cash effects of changes in: Other non-current assets 35 28 53 +25.00%
Cash effects of changes in: Other non-current liabilities (95) (44) (64) +115.91%
Net cash provided by operations 4,198 4,107 3,745 +2.22%
Capital expenditures (564) (561) (705) +0.53%
Purchases of marketable securities and investments (698) (574) (506) +21.60%
Proceeds from sale of marketable securities and investments 752 564 502 +33.33%
Payment for acquisitions, net of cash acquired (293) 0 0 N/M
Other investing activities (14) 37 (33) N/M
Net cash used in investing activities (817) (534) (742) +53.00%
Short-term borrowing (repayment) less than 90 days, net (989) 93 (906) N/M
Principal payments on debt (655) (503) (903) +30.22%
Proceeds from issuance of debt 1,188 2 1,495 +59300.00%
Dividends paid (1,823) (1,789) (1,749) +1.90%
Purchases of treasury shares (1,210) (1,739) (1,128) -30.42%
Proceeds from exercise of stock options 101 638 380 -84.17%
Other financing activities 132 (91) 18 N/M
Net cash used in financing activities (3,256) (3,389) (2,793) -3.92%
Effect of exchange rate changes on Cash and cash equivalents 67 (54) (19) N/M
Net increase (decrease) in Cash and cash equivalents 192 130 191 +47.69%
Cash and cash equivalents at beginning of year 1,096 966 775 +13.46%
Cash and cash equivalents at end of year 1,288 1,096 966 +17.52%

Investing cash outflows expanded to $817 million in 2025, driven by the net $293 million cash consideration paid for Care TopCo Pty Ltd. Financing outflows absorbed $3,256 million, led by $1,823 million in common stock dividends and $1,210 million in open market and plan-related treasury share repurchases, balanced against $1,188 million of proceeds from new debt issuances.

Funding the Future: R&D and Expansion Spending

The enterprise allocated substantial capital toward proprietary laboratory innovation and operational facility modernizations to maintain its competitive position:

  • Research and Development Expenses: Dedicated R&D investments totaled $366 million in 2025, $355 million in 2024, and $343 million in 2023, classified inside Selling, general and administrative expenses. R&D centers in New Jersey, Kansas, and Mexico focus on oral care bio-actives, dermatological formulations, household packaging circularity, and therapeutic pet clinical diets.
  • Capital Expenditures: Additions to property, plant and equipment were $564 million in 2025, compared to $561 million in 2024 and $705 million in 2023. Capital allocations in 2025 were directed toward Oral, Personal and Home Care ($361 million total, including $141 million in Latin America and $80 million in Asia Pacific), Hill’s Pet Nutrition ($88 million), and Corporate systems and facilities ($115 million).
  • Capital Expenditure Outlook: Management projects 2026 capital expenditures to approximate 3.0% of Net sales.
  • Commercial Advertising Investment: Direct advertising investment reached $2,703 million in 2025, representing 13.3% of Net sales, compared to $2,720 million (13.5% of Net sales) in 2024 and $2,371 million in 2023.

4. The Corporate Family Tree: Colgate-Palmolive Company Subsidiaries & Acquisitions

Subsidiaries, Associates, & Shared Ventures

The parent corporation controls domestic operating companies, regional financing subsidiaries, and foreign operational entities spanning over 80 legal jurisdictions outside the United States. Key operational legal entities and recent corporate transactions include:

  • Care TopCo Pty Ltd: Acquired on April 30, 2025, for cash consideration of AU $471 million (approximately $301 million). It owns the Prime100 fresh pet food business in Australia and was integrated into Hill’s Pet Nutrition. The acquisition added $207 million in goodwill and $64 million in other intangible assets.
  • Hill’s Pet Nutrition, Inc.: Primary operating subsidiary overseeing global companion animal dietary operations across North America, Europe, Asia, and Latin America.
  • Brazilian Subsidiary: Colgate-Palmolive’s primary operating entity in Brazil, which holds the 1995 Kolynos acquisition assets and is party to tax appeals in Brazilian federal courts.
  • Laboratorios Wyeth-Whitehall Ltda.: Brazilian operating subsidiary of Wyeth (the Seller of Kolynos), named alongside Colgate’s Brazilian subsidiary in legacy 2002 tax litigation.

Strategic Investments & Minority Stakes

The company maintains noncontrolling equity ownership stakes ranging between 20% and 50% in select consumer product businesses where it exercises significant operational influence:

  • Equity Method Investments: Total carrying value of equity method investments recorded in Other assets on the Consolidated Balance Sheets was $82 million at December 31, 2025, and $81 million at December 31, 2024.
  • Equity Income: Pretax equity income generated from these investments was $20 million in 2025, $22 million in 2024, and $17 million in 2023, reported as a component of Other (income) expense, net.
  • Noncontrolling Interests: Third-party minority equity holders’ portion of consolidated subsidiaries was valued at $311 million on the balance sheet at December 31, 2025 ($332 million in 2024), with $129 million of consolidated 2025 net income distributed to noncontrolling interests ($160 million in 2024).

5. Power & Control: Colgate-Palmolive Company Executive Leadership & Ownership

The Brain Trust: Board of Directors & Executive Leadership

Corporate executive governance is headed by an executive management team and overseen by the Board of Directors, which delegates specialized oversight responsibilities to the Audit Committee, the Personnel and Organization Committee, and the Nominating, Governance and Corporate Responsibility Committee.

The executive officers of Colgate-Palmolive Company as of February 23, 2026, include:

  • Noel Wallace (Chairman of the Board, President and Chief Executive Officer): Age 61; first elected an executive officer in 2009; leads global enterprise strategy, operations, and the Enterprise Risk Management Committee.
  • Stanley J. Sutula III (Chief Financial Officer): Age 60; first elected an executive officer in 2020; oversees global financial strategy, treasury, controller operations, internal audit, and information technology.
  • Jennifer M. Daniels (Chief Legal Officer and Secretary): Age 62; first elected an executive officer in 2014; manages global legal affairs, regulatory compliance, corporate governance, and litigation defense.
  • Shane Grant (Chief Operating Officer, Americas): Age 51; joined the company and elected executive officer in 2025; previously served as Group Deputy CEO, CEO Americas and EVP Dairy, Plant-Based and Global Sales at Groupe Danone since January 2023, having joined Danone in May 2020 as EVP & CEO Danone North America.
  • John Hazlin (Chief Growth Officer): Age 56; elected executive officer in 2025; directs omni-channel commercialization, digital demand generation, and brand growth strategies.
  • Panagiotis Tsourapas (Chief Operating Officer, Europe, Asia Pacific, Africa/Eurasia, Skin Health and Global Customer Development): Age 61; first elected an executive officer in 2019; directs regional operations across international territories and specialized skin health units.
  • Sally Massey (Chief Human Resources Officer): Age 52; first elected an executive officer in 2020; oversees global workforce management, succession planning, and total rewards.
  • Gregory O. Malcolm (Executive Vice President, Controller): Age 58; first elected an executive officer in 2022; leads enterprise accounting operations, external financial reporting, and internal reporting controls.

Who Owns the Stock?

As of January 31, 2026, there were 801,548,028 shares of Colgate-Palmolive Company Common Stock ($1.00 par value) issued and outstanding.

Plan Category / Equity Instrument Number of Securities to be Issued Upon Exercise (in thousands) Weighted-Average Exercise Price Number of Securities Remaining Available for Future Issuance (in thousands)
Equity compensation plans approved by security holders 15,607 $80.25 24,155
Total Stock Incentive Pool 15,607 $80.25 24,155

The total equity compensation balance of 15,607 thousand securities consists of 12,619 thousand stock options outstanding (weighted-average exercise price of $79), 2,058 thousand unvested time-based restricted stock units (weighted-average grant price of $88), and 930 thousand unearned performance-based restricted stock units (weighted-average grant price of $80) granted under the 2019 Incentive Compensation Plan.

  • Employee Stock Ownership Plan (ESOP): As of December 31, 2025, 6,646,688 shares of common stock were outstanding and issued to the Company’s ESOP (down from 7,428,343 shares in 2024). All shares have been fully released and allocated to participant accounts. The ESOP had no outstanding borrowings from the company.
  • Share Repurchase Authorization: On March 20, 2025, the Board authorized a $5 billion share repurchase program (the “2025 Program”), replacing the prior 2022 authorization. During 2025, the company acquired 13.7 million common shares under the board authorizations and 0.6 million shares for employee plans, totaling $1,210 million in treasury cash outlays.
  • Institutional Customer Weight: Sales to Walmart, Inc. and its retail affiliates represented approximately 11% of consolidated Net sales in 2025, 2024, and 2023. No other retail trade customer accounted for 10% or more of net sales.

6. Strategic Outlook: Colgate-Palmolive Company Growth Catalysts & Key Risks

Competitive Advantages & Economic Moats

The company maintains economic advantages grounded in global brand penetration, scientific endorsement, and retail shelf footprint across diverse geographies:

  • Global Brand Leadership: Colgate operates as the world’s most penetrated consumer brand, maintaining a 41.3% global market share in toothpaste and a 32.4% share in manual toothbrushes, alongside leadership in liquid hand soaps via Palmolive, Protex, and Softsoap.
  • Veterinary & Professional Relationships: Hill’s Prescription Diet and professional Oral Care lines maintain clinical recommendations and direct commercial pipelines through veterinarians, dental practitioners, and clinics.
  • Deep International Sourcing & Distribution: Operating with local manufacturing and distribution facilities across Latin America, Europe, Asia Pacific, and Africa/Eurasia reduces supply lead times and creates physical scale advantages over local competitors.

What Could Go Wrong? Key Challenges & Business Risks

The enterprise faces complex operational, geopolitical, legal, and regulatory risks across its operating segments:

  • Raw and Packaging Material Cost Inflation: The business is exposed to market price volatility in commodities, including agricultural inputs (corn, poultry, tallow, soybeans), resins, pulp, essential oils, and tropical oils. In 2025, raw and packaging material cost increases burdened gross margin by 420 basis points.
  • Foreign Exchange and Hyper-Inflationary Exposure: Generating two-thirds of revenue outside the U.S. exposes profits to dollar appreciation. Macroeconomic disruptions and currency adjustments remain acute in hyper-inflationary markets such as Argentina, Nigeria, and Türkiye.
  • Global Trade and Tariff Tensions: Developments in trade relations, including potential and implemented tariffs under 2025 U.S. executive orders, reciprocal foreign tariffs, and the potential renegotiation of the United States-Mexico-Canada Agreement (USMCA), present risks of input cost increases, consumer spending contraction, and supply chain friction.
  • Retail Consolidation and Channel Shifts: Rising retail customer bargaining strength, retailer expansion of private label alternatives, e-commerce direct-to-consumer expansion, automated retailer inventory destocking, and AI-driven pricing algorithms pressure supplier margins.
  • Geopolitical and Regional Disruption: Geopolitical tensions, military conflicts in Ukraine and the Middle East, and ongoing political uncertainties in Venezuela impact regional supply logistics, energy costs, and raw material availability. Operations in the Eurasia region constituted approximately 1% of consolidated net sales and 2% of consolidated operating profit in 2025.
  • Legal Contingencies & Talcum Powder Actions: The company is named as a defendant in 454 active civil actions in U.S. federal and state courts alleging asbestos contamination and cancer caused by legacy talcum powder lines (up from 308 cases in 2024). The company estimates the aggregate range of reasonably possible losses in excess of accrued liabilities for quantifiable legal matters at $0 to approximately $225 million.
  • Brazilian Tax Litigation: The enterprise continues to dispute Brazilian internal revenue assessments disallowing interest deductions and foreign exchange losses associated with the 1995 Kolynos acquisition, with total claims, interest, and penalties approximating $97 million, alongside related capital gain and treasury transaction tax claims.
  • Goodwill & Intangible Asset Impairments: Weaker performance and category softness in skin health, particularly regarding the Filorga business in China, resulted in $919 million of non-cash impairment charges in 2025. Further consumer weakness could result in additional charges.

The Next Chapter: Growth & Expansion Initiatives

Having completed its 2025 strategic plan, Colgate-Palmolive initiated its 2030 business strategy focused on core brand penetration, science-based core and premium innovation, omni-channel demand generation, and accelerated organizational efficiency.

  • Strategic Growth and Productivity Program: Approved by the Board on July 31, 2025, this three-year restructuring initiative aims to optimize the global supply chain, streamline regional overhead, and reallocate capital toward fast-growing divisions. The program is projected to generate cumulative pretax charges between $200 million and $300 million ($13 million incurred in 2025), with 75% to 85% resulting in cash expenditures, concluding by December 31, 2028. Charges are expected across North America (15-20%), Latin America (15-20%), Europe (10-15%), Asia Pacific (10-15%), Pet Nutrition (10-15%), Corporate (10-15%), and Africa/Eurasia (5-10%).
  • Fresh Pet Category Expansion: The integration of Prime100 provides Hill’s Pet Nutrition with an entry point into Australia’s refrigerated fresh pet food category, establishing a base for prospective international expansion into alternative animal nutrition formats.
  • Funding-the-Growth Efficiency Drive: Ongoing company-wide initiatives targeting raw material substitutions, packaging reductions, SKU simplification, and procurement consolidations delivered 260 basis points of gross margin savings in 2025, offsetting a significant portion of commodity inflation.

The Verdict: Strategic Outlook & Conclusion

Colgate-Palmolive enters 2026 managing persistent category softness, higher raw and packaging material expenses, currency volatility, and evolving international trade policies. However, its broad operational footprint, global leadership in essential oral hygiene categories, steady free cash flow generation exceeding $4 billion annually, and disciplined productivity programs provide the structural resources required to defend margins and invest behind its 2030 strategic objectives.

❓ Frequently Asked Questions: Colgate-Palmolive Company

What was Colgate-Palmolive Company’s revenue and net income in FY 2025?

In FY 2025, Colgate-Palmolive Company reported total revenue of $20.38 B (▲ 1.4% compared to $20.10 B in the prior fiscal year). Gross profit stood at $12.25 B (gross margin of 60.11 %). Operating profit was $3.31 B and bottom-line net income was $2.13 B.

Is Colgate-Palmolive Company profitable and generating positive cash flow in FY 2025?

Yes, Colgate-Palmolive Company was profitable in FY 2025, recording net profit of $2.13 B (PAT margin: 10.46 %). On a cash basis, the company generated $4.20 B in cash flow from operating activities and invested $564.00 M in capital expenditures, resulting in free cash flow of $3.63 B. Return on Equity (ROE) was 584.11 % and Cash ROE was 1150.14 %.

How much debt, assets, and equity does Colgate-Palmolive Company hold?

As of FY 2025, Colgate-Palmolive Company held $16.33 B in total assets, $15.96 B in total liabilities, and $365.00 M in total stockholders’ equity. Total debt stood at $7.99 B (debt-to-equity ratio of 21.88x). Net working capital was -$1.14 B with a current ratio of 0.83x.

Who is the CEO and CFO of Colgate-Palmolive Company?

The Chief Executive Officer (CEO) of Colgate-Palmolive Company is Noel Wallace. The Chief Financial Officer (CFO) is Stanley J. Sutula III.

Where is Colgate-Palmolive Company headquartered and when was it founded?

Colgate-Palmolive Company is headquartered in 300 Park Avenue, New York, New York 10022. The company traces its founding/incorporation to Delaware. Total disclosed workforce/headcount is Approximately 33,600 employees. Its official corporate website is www.colgatepalmolive.com.

Note: Financial ratios, margins, year-over-year (YoY) growth rates, and percentage shares of revenue are calculated by FirmsWorld based on figures reported in the company’s official SEC filing.